Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Seres Therapeutics Inc is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Seres Therapeutics employs 333 staff and has a trailing 12-month revenue of around $136.7 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $6.42 |
|---|---|
| 52-week range | $2.50 - $11.69 |
| 50-day moving average | $5.27 |
| 200-day moving average | $5.95 |
| Wall St. target price | $13.14 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.94 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.42 from 2022-09-30
| 1 week (2022-09-23) | 9.00% |
|---|---|
| 1 month (2022-09-01) | 23.70% |
| 3 months (2022-07-01) | 76.86% |
| 6 months (2022-03-28) | N/A |
| 1 year (2021-10-01) | -11.33% |
|---|---|
| 2 years (2020-10-01) | -76.82% |
| 3 years (2019-10-01) | 64.62% |
| 5 years (2017-09-29) | 16.04 |
| Revenue TTM | $136.7 million |
|---|---|
| Gross profit TTM | $3 million |
| Return on assets TTM | -23.05% |
| Return on equity TTM | -166.19% |
| Profit margin | -75.48% |
| Book value | $0.25 |
| Market capitalisation | $744.4 million |
TTM: trailing 12 months
We're not expecting Seres Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $2.5 up to $11.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 3.01. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Seres Therapeutics, Inc. , a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.